Can ultra-High-Throughput Screening be exploited to identify novel compounds against protein mulitmerization?

Watch this webinar on September 28, 16.00 hrs. (CET) and learn about:

  • Development, optimization and miniaturization of screening assay cascade
  • ultra-High-Throughput Screening of al large compound library
  • Hit validation and triaging

The innate immune system is crucial for initiation and amplification of inflammatory responses and tissue destruction in many diseases. Calcium binding proteins plays a major role in Immune-Mediated Inflammatory Diseases, some of which are currently used as diagnostic biomarkers in a subset of inflammatory diseases. Several pro-inflammatory functions have been ascribed to calcium binding proteins and as such, making them solid targets for small-molecule therapeutics.

About the presenter:

Dr. Saman Honarnejad –  Director Drug Discovery at Pivot Park Screening Centre is a biotechnologist with over a decade of experience in high-throughput biology. At Pivot Park Screening Centre (PPSC) in Oss, the Netherlands, he is involved in cellular and biochemical assay development, ultra high-throughput screening (uHTS) and hit-to-lead biological compound profiling within a wide range of commercial, academic and public-private partnership projects including the European Lead Factory (ELF).

Prior to joining PPSC in 2017, he was active in high-content compound profiling method development at Max-Planck Institute (Germany), Harvard Medical School (United States) and Heidelberg University (Germany) and further optimized microarray-based cDNA/RNAi functional screening assays at the European Molecular Biology Laboratory (EMBL).

(Duration of this webinar is 45 minutes)